Does Medicare Cover Diabetic Retinopathy? Eye Exams, Injections, and 2026 Costs

Yes - Medicare covers diabetic retinopathy treatment under Part B, including annual dilated eye exams for people with diabetes, anti-VEGF injections, laser photocoagulation, intravitreal steroid implants, and vitrectomy for advanced disease. Because anti-VEGF drugs are injected in a physician’s office, they are billed under Part B - not Part D - and cost-sharing can reach $4,000 to $5,000 per year for patients receiving monthly injections without supplemental coverage.

Diabetic retinopathy is the most common microvascular complication of diabetes and the leading cause of new blindness in working-age adults. Among Medicare beneficiaries, the stakes are even higher: roughly 27 percent of Medicare patients have diabetes, and diabetic retinopathy eventually affects most people who have lived with diabetes for 20 years or more. For many Medicare beneficiaries, the cost of treatment - especially the cost of ongoing anti-VEGF injections - is the most significant Part B out-of-pocket expense they will face.

This guide explains exactly what Medicare pays for, what it does not cover, what you should expect to spend in 2026, and how supplemental coverage can protect you from the highest costs.

What Is Diabetic Retinopathy?

Diabetic retinopathy is damage to the blood vessels in the retina - the light-sensitive tissue at the back of the eye - caused by chronically elevated blood glucose. High blood sugar weakens retinal capillaries, causing them to leak fluid, bleed, or grow abnormally. The disease progresses through two main stages:

Non-proliferative diabetic retinopathy (NPDR): The early stage. Blood vessel walls weaken, forming tiny bulges called microaneurysms that leak blood and fluid into the retina. Patients may have no symptoms or notice only mild blurring. NPDR can be mild, moderate, or severe depending on how many blood vessels are affected.

Proliferative diabetic retinopathy (PDR): The advanced stage. The retina, deprived of oxygen, responds by growing fragile new blood vessels across its surface and into the vitreous cavity. These new vessels bleed easily, causing vitreous hemorrhage (sudden dark floaters or complete vision loss). Scar tissue can develop and contract, causing tractional retinal detachment. PDR is the primary cause of blindness from diabetic retinopathy.

Diabetic macular edema (DME): Fluid accumulation in the macula - the central retina responsible for sharp, detailed vision. DME can occur at any stage of retinopathy and is the most common cause of vision loss associated with diabetes. Treatment for DME is the most expensive component of diabetic retinopathy care.

Medicare Part B: Annual Diabetic Eye Exam

Medicare Part B covers one dilated eye exam per year for people with diabetes to screen for diabetic retinopathy. This is a preventive benefit specific to diabetes - it is different from the routine vision exam Medicare does not cover.

The exam must be performed by an ophthalmologist or optometrist who is legally authorized to perform eye exams in your state. The standard 20% coinsurance applies after the Part B deductible unless the provider accepts assignment, in which case Medicare pays 80% of the approved amount and you pay 20%.

This annual exam is a critical benefit. Diabetic retinopathy frequently causes no symptoms until vision loss is severe, and the only reliable way to catch it early - when treatment can preserve vision - is through regular dilated fundus examination.

Patients with diagnosed retinopathy may need more frequent monitoring. If your ophthalmologist recommends exams every 3 to 6 months due to active disease, those additional exams are covered under Part B as medically necessary visits, not as the annual preventive benefit. The standard 80/20 cost-sharing applies.

Medicare Part B: Diagnostic Testing

When diabetic retinopathy is detected or suspected, Medicare Part B covers the diagnostic tests needed to characterize the disease and guide treatment decisions. All of the following are covered when ordered by a treating physician:

Optical coherence tomography (OCT): A non-invasive imaging test that creates detailed cross-sectional images of the retina, measuring retinal thickness and identifying fluid within or beneath retinal layers. OCT is the standard tool for diagnosing and monitoring DME and is performed at virtually every ophthalmology visit for retinopathy patients. Standard Part B cost-sharing applies.

Fluorescein angiography: A dye is injected intravenously, and photographs of the retina are taken as the dye circulates. The test identifies leaking blood vessels, areas of non-perfusion, and new vessel growth. It guides laser treatment planning and helps distinguish between types of macular edema. Part B covers fluorescein angiography when medically indicated.

Fundus photography: Wide-field or ultra-wide-field photographs of the retina document the extent and severity of retinopathy, track progression over time, and sometimes detect new vessels or hemorrhages without dilation. Part B covers retinal photography when ordered for diagnostic purposes.

Visual field testing: For patients with PDR or severe NPDR, visual field testing documents peripheral vision loss from retinal damage or treatment effects. Covered under Part B when medically necessary.

Medicare Part B: Anti-VEGF Injections

Anti-VEGF (anti-vascular endothelial growth factor) injections are the primary treatment for diabetic macular edema and for active proliferative diabetic retinopathy. These drugs are injected directly into the vitreous cavity of the eye - intravitreal injection - in an ophthalmologist’s office. Because the drug is administered by a physician rather than self-administered, Medicare bills it under Part B as a physician-administered drug, not under Part D.

This distinction matters enormously for cost-sharing. Under Part B, you owe 20% of the Medicare-approved amount for the drug plus a separate administration fee. For the most expensive agents, that 20% can exceed $400 per injection.

Medicare-approved anti-VEGF drugs for DME and PDR as of 2026:

Eylea (aflibercept): FDA-approved for DME, PDR, and wet AMD. The standard reference drug for many retinal specialists. Medicare reimburses at the Average Sales Price (ASP) plus 6%. Wholesale Acquisition Cost approximately $2,350 per vial. Patient’s 20%: approximately $450-$500 per injection, before the deductible.

Lucentis (ranibizumab): FDA-approved for DME and other retinal diseases. WAC approximately $1,900 per vial. Patient’s 20%: approximately $380-$400 per injection.

Vabysmo (faricimab): FDA-approved for DME and wet AMD; a newer bispecific antibody that blocks both VEGF-A and Ang-2. WAC approximately $2,450 per vial. Some patients require injections every 16 weeks after loading doses, which can reduce total annual costs. Patient’s 20%: approximately $460-$490 per injection.

Biosimilars to Lucentis (Byooviz, Cimerli): FDA-approved biosimilars to ranibizumab, reimbursed at a slight discount to Lucentis. Covered under Part B.

Biosimilars to Eylea (Yesafili, Opuviz): Aflibercept biosimilars approved for DME and wet AMD indications. Covered under Part B at a slight discount.

Avastin (bevacizumab): FDA-approved for cancer, but widely used off-label for DME, PDR, and wet AMD. The drug must be compounded (diluted into individual doses) by a compounding pharmacy. Medicare covers it as a medically accepted off-label use. Compounded bevacizumab costs approximately $65 to $85 per dose - dramatically lower than Eylea or Lucentis. Patient’s 20%: approximately $13 to $17 per injection. Many retinal specialists use Avastin as first-line treatment because outcomes data show comparable efficacy for many patients at a fraction of the cost.

For a patient receiving 10 injections per year (a common early treatment schedule for active DME):

DrugCost per Injection (20%)Annual Cost (10 injections)
Avastin (bevacizumab compounded)~$15~$150
Lucentis biosimilar~$380~$3,800
Lucentis (ranibizumab)~$400~$4,000
Eylea (aflibercept)~$475~$4,750
Vabysmo (faricimab)~$490~$4,900

These are drug costs only. Each injection also carries a Part B-covered physician administration fee (approximately $72 in 2026), of which you owe 20% (approximately $14).

The choice of drug is a significant financial decision. Discuss Avastin with your retinal specialist - for many patients with DME, the evidence supports comparable outcomes to the brand agents at approximately 3% of the cost.

Medicare Part B: Laser Photocoagulation

Before anti-VEGF became the standard of care for DME, laser photocoagulation was the primary treatment. It remains an important option for certain patients and situations.

Focal/grid laser photocoagulation: Used for some forms of DME, particularly when macular edema is focal and not at the center of the macula. A laser is applied to leaking blood vessels to seal them and reduce fluid accumulation. Covered under Part B as an outpatient surgical procedure. The patient’s 20% typically ranges from $200 to $600 depending on complexity and setting.

Panretinal photocoagulation (PRP): The standard treatment for proliferative diabetic retinopathy not managed with anti-VEGF. The laser is applied across the peripheral retina in a scatter pattern, destroying oxygen-deprived tissue and signaling the retina to stop producing VEGF. PRP is typically performed in 1 to 2 sessions. Covered under Part B. Patient’s 20% is similar to focal laser.

Laser treatment is typically a one-time or limited-session procedure rather than an ongoing monthly treatment, making the total cost lower than years of anti-VEGF injections.

Medicare Part B: Vitrectomy

Vitrectomy is surgery to remove the vitreous gel from the eye. It is performed for advanced PDR complications: vitreous hemorrhage (blood in the vitreous that blocks vision and does not clear on its own), tractional retinal detachment (scar tissue pulling the retina away from the wall of the eye), or combined tractional/rhegmatogenous detachment.

Vitrectomy is usually performed as outpatient surgery at an ambulatory surgery center or hospital outpatient department, billed under Part B. The patient’s 20% coinsurance typically ranges from $1,000 to $3,500 depending on the facility and complexity. The Part B deductible ($257 in 2026) also applies if not already met.

In rare cases requiring concurrent inpatient admission, Part A applies: the $1,676 inpatient deductible (2026) covers the first 60 days of an inpatient stay, and skilled nursing facility eligibility may follow.

Medicare Part B: Intravitreal Steroid Implants

For DME patients who do not respond adequately to anti-VEGF therapy or who cannot tolerate repeated injections, Medicare Part B covers intravitreal steroid implants:

Ozurdex (dexamethasone implant, 0.7 mg): A biodegradable implant injected into the vitreous that releases dexamethasone over approximately 3 to 6 months. FDA-approved for DME. WAC approximately $1,200. Patient’s 20%: approximately $240 per implant. Patients typically receive 2 to 3 implants per year. Important consideration: steroids can raise intraocular pressure and accelerate cataract formation.

Iluvien (fluocinolone acetonide, 0.19 mg): A tiny non-biodegradable implant that releases fluocinolone acetonide continuously for approximately 36 months. FDA-approved for chronic DME unresponsive to other treatments. WAC approximately $8,000 to $9,000. Patient’s 20%: approximately $1,600 to $1,800 per implant. The 3-year duration means one implant replaces 36+ monthly anti-VEGF injections for some patients.

Both are Part B physician-administered drugs subject to the 80/20 cost-sharing framework.

2026 Cost Summary

ServiceMedicare Part2026 Patient Cost (without Medigap)
Annual diabetic eye examPart B preventive$0-57 (20% if provider charges above assignment)
OCT imagingPart B20% after $257 deductible
Fluorescein angiographyPart B20% after $257 deductible
Avastin injection (drug + admin)Part B~$30 per injection
Eylea injection (drug + admin)Part B~$490 per injection
Lucentis injection (drug + admin)Part B~$415 per injection
Focal laser photocoagulationPart B~$200-$600 (one-time or limited sessions)
Panretinal photocoagulationPart B~$300-$700 per session
Vitrectomy (outpatient)Part B~$1,000-$3,500
Ozurdex implantPart B~$240 per implant
Iluvien implantPart B~$1,600-$1,800 per implant
Part B annual deductible$257 (applies once per year)

What Medicare Does NOT Cover

Routine vision exams: Medicare does not cover routine eye exams for glasses or contacts. The annual diabetic eye exam is specifically for diabetic retinopathy screening - it is not a routine vision exam with a refractive component.

Eyeglasses and contact lenses: Medicare does not cover prescription eyeglasses or contacts except for one standard pair of glasses (or contact lenses) after cataract surgery with intraocular lens implantation. Vision changes from diabetic retinopathy or treatment do not trigger eyeglass coverage.

Over-the-counter supplements: Supplements marketed for eye health (lutein, zeaxanthin, AREDS2 formulas) are not covered by Medicare Part B or Part D. Note that AREDS2 supplementation has evidence for slowing AMD progression - but it has not been shown to slow diabetic retinopathy progression. Medicare does not cover supplements in either context.

Non-approved therapies: Treatments not FDA-approved or recognized as medically accepted indications for diabetic retinopathy are not covered.

Medicare Advantage and Prior Authorization

Medicare Advantage plans are required to cover the same services as Original Medicare, but they frequently require prior authorization before approving expensive treatments like anti-VEGF injections, Ozurdex, and Iluvien.

Prior authorization for anti-VEGF injections typically requires:

  • Documentation of the DME or PDR diagnosis with OCT evidence of fluid or new vessel growth
  • Confirmation that the drug requested is on-formulary for the plan (some plans favor specific anti-VEGF agents)
  • For more expensive drugs (Vabysmo, Eylea), some plans may require a trial of Avastin or a Lucentis biosimilar first (step therapy)

For vitrectomy, prior authorization is standard. Plans will typically require documentation of vitreous hemorrhage or tractional retinal detachment not amenable to laser treatment.

If your Medicare Advantage plan denies a service, you have the right to appeal within 60 days of the denial notice. For urgent situations where delay risks permanent vision loss, request an expedited appeal (72-hour response).

Network restrictions are another consideration. Many Medicare Advantage plans require you to use network retinal specialists. For beneficiaries in rural areas or with established relationships with specific ophthalmology practices, this can be a significant constraint.

Medigap Plan G: The Most Protective Option for Anti-VEGF Patients

For patients with active DME or PDR requiring ongoing anti-VEGF injections, Medigap Plan G provides the most financial protection available under Original Medicare. Plan G pays 100% of the Part B coinsurance after you pay the annual Part B deductible ($257 in 2026). This means:

  • Monthly Eylea injections: effectively free after the $257 deductible
  • Monthly OCT monitoring: free
  • Laser treatment: free
  • Vitrectomy: free (hospital costs covered under Part A with Plan G covering the Part A coinsurance)

For a patient receiving 10 Eylea injections per year at $490 per injection, Plan G saves approximately $4,750 in drug coinsurance alone. Plan G typically costs $100 to $200 per month in premiums depending on age and state - often less than the annual out-of-pocket savings for a single year of active treatment.

For detailed plan-by-plan comparisons including cost and coverage, see the Medigap plans compared guide.

Medicare Savings Programs

Beneficiaries with limited income and assets may qualify for Medicare Savings Programs (MSPs) that pay some or all Medicare cost-sharing:

Qualified Medicare Beneficiary (QMB): Pays all Part A and Part B premiums, deductibles, and coinsurance. For a patient receiving regular anti-VEGF injections, QMB eliminates 100% of the out-of-pocket costs for injections, OCT, and office visits. Providers are prohibited by law from billing QMB beneficiaries for any cost-sharing.

Specified Low-Income Medicare Beneficiary (SLMB) and Qualifying Individual (QI): Pay the Part B premium only.

Income and asset limits vary by state. Apply through your state Medicaid office or use the Medicare Savings Programs guide for eligibility details and application steps.

Action Steps for Medicare Beneficiaries with Diabetic Retinopathy

Step 1 - Schedule your annual dilated eye exam. Even if you have no visual symptoms, get a dilated eye exam once per year. Many Medicare beneficiaries with early NPDR or early DME have no symptoms. Early detection is the difference between medical management and surgical intervention.

Step 2 - Ask your retinal specialist about Avastin. If you are starting anti-VEGF therapy for DME or PDR, ask whether bevacizumab (Avastin) is an appropriate first-line option. For many patients the evidence shows comparable outcomes to Eylea and Lucentis at approximately 3% of the cost. This is not a quality-of-care compromise - it is evidence-based practice at major academic retina centers.

Step 3 - Check your supplemental coverage before your first injection. If you are on Original Medicare only, calculate your projected annual out-of-pocket based on the injection frequency your doctor anticipates. If the total exceeds $2,000 per year, compare the cost of Medigap Plan G premiums against your expected out-of-pocket.

Step 4 - For Medicare Advantage, obtain prior authorization before the first injection. Confirm your plan’s prior authorization process for anti-VEGF drugs and confirm your retinal specialist is in-network. Begin the prior authorization process before your scheduled injection date to avoid delays.

Step 5 - Apply for Medicare Savings Programs if your income is limited. QMB enrollment eliminates all Part B cost-sharing, including the full cost of anti-VEGF injections, OCT, and office visits. Apply through your state Medicaid office - even if you think you may not qualify, eligibility rules are more generous than many people expect.

Frequently Asked Questions

Does Medicare cover Eylea injections for diabetic retinopathy?

Yes. Eylea (aflibercept) is covered under Medicare Part B as a physician-administered drug for diabetic macular edema and proliferative diabetic retinopathy. The patient’s 20% coinsurance applies after the Part B deductible. At current pricing, 20% of the Medicare-approved amount is approximately $450 to $500 per injection. Medigap Plan G covers this coinsurance entirely.

Does Medicare cover Avastin injections for diabetic retinopathy?

Yes. Although Avastin (bevacizumab) is FDA-approved for cancer rather than retinal disease, intravitreal Avastin for diabetic macular edema is a medically accepted off-label use covered by Medicare Part B. The patient’s 20% of the compounded drug cost is approximately $13 to $17 per injection - dramatically lower than brand agents.

Does Medicare cover the annual diabetic eye exam?

Yes. Medicare Part B covers one dilated eye exam per year specifically for people with diabetes to screen for diabetic retinopathy. This is a diabetes-specific benefit separate from routine vision care, which Medicare does not cover. The 20% coinsurance applies.

Is laser treatment for diabetic retinopathy covered by Medicare?

Yes. Both focal/grid laser photocoagulation for diabetic macular edema and panretinal photocoagulation for proliferative diabetic retinopathy are covered under Medicare Part B as medically necessary surgical procedures. The standard 20% coinsurance applies after the Part B deductible.

Does Medicare cover vitrectomy for vitreous hemorrhage?

Yes. Vitrectomy for complications of proliferative diabetic retinopathy - including vitreous hemorrhage and tractional retinal detachment - is covered under Part B when performed in an outpatient setting. The 20% coinsurance can range from $1,000 to $3,500 depending on facility and complexity.

Does Medicare cover OCT scans for diabetic retinopathy monitoring?

Yes. Optical coherence tomography (OCT) is covered under Medicare Part B as a diagnostic imaging test when ordered by a treating physician for the diagnosis or monitoring of diabetic retinopathy or diabetic macular edema. The 20% coinsurance applies.

Will Medicare Advantage require prior authorization for anti-VEGF injections?

Most Medicare Advantage plans require prior authorization for anti-VEGF injections. The process typically requires documentation of the DME or PDR diagnosis, OCT evidence of active disease, and confirmation of medical necessity. Some plans also apply step therapy, requiring a trial of Avastin or a biosimilar before approving brand-name agents. Contact your plan before your first injection to understand the requirements.

Can I get both Medicare diabetic retinopathy treatment and diabetic neuropathy treatment covered at the same time?

Yes. Medicare Part B covers treatment for multiple diabetic complications simultaneously. Diabetic retinopathy treatment (anti-VEGF injections, laser, vitrectomy) and diabetic neuropathy treatment (nerve conduction studies, physical therapy, medications) are separate covered benefits with separate cost-sharing calculations. For beneficiaries managing multiple diabetic complications, QMB or Medigap Plan G is especially valuable because the cumulative out-of-pocket can be substantial.

Sources

Reviewed by Alex Johnson, Editor. All sources are official government or academic resources, verified November 2026. Medicare costs and coverage rules change annually - confirm current figures at the links above before making decisions.